OmniAb Inc expected to post a loss of 12 cents a share - Earnings Preview
OmniAb Inc expected to post a loss of 12 cents a share - Earnings Preview
OmniAb Inc OABI.OQ OABI.O is expected to show a rise in quarterly revenue when it reports results on August 6 for the period ending June 30 2026
The Emeryville California-based company is expected to report a 20.4% increase in revenue to $4.693 million from $3.9 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for OmniAb Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for OmniAb Inc is $8.00, about 308.2% above its last closing price of $1.96
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.10 | -0.10 | -0.06 | Beat | 40 |
Dec. 31 2026 | -0.09 | -0.09 | -0.11 | Missed | -24.2 |
Sep. 30 2025 | -0.13 | -0.14 | -0.14 | Met | 0 |
Jun. 30 2025 | -0.16 | -0.15 | -0.15 | Met | 2.4 |
Mar. 31 2025 | -0.16 | -0.16 | -0.17 | Missed | -3.7 |
Dec. 31 2024 | -0.11 | -0.11 | -0.12 | Missed | -6.5 |
Sep. 30 2024 | -0.14 | -0.14 | -0.16 | Missed | -16.5 |
Jun. 30 2024 | -0.17 | -0.17 | -0.13 | Beat | 23.3 |
This summary was machine generated August 4 at 20:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on OmniAB
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
OmniAb rises on drug discovery deal with Lilly worth up to $370 million
U.S. STOCKS ON THE MOVE - KBR, Vista Energy, Fulcrum Therapeutics
OmniAb rises on drug discovery deal with Lilly worth up to $370 mln